共 50 条
Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer
被引:18
作者:
Chang, Myung Hee
[1
,5
]
Lee, Kyungji
[2
]
Lee, Kyo-Young
[2
]
Kim, Yeon Sil
[3
]
Kim, Young Kyoon
[4
]
Kang, Jin-Hyoung
[1
]
机构:
[1] Catholic Univ, Div Oncol, Dept Med, Seoul St Marys Hosp,Sch Med, Seoul 137701, South Korea
[2] Catholic Univ, Dept Hosp Pathol, Sch Med, Seoul St Marys Hosp, Seoul 137701, South Korea
[3] Catholic Univ, Dept Radiat Oncol, Sch Med, Seoul St Marys Hosp, Seoul 137701, South Korea
[4] Catholic Univ, Div Pulmonol, Sch Med, Seoul St Marys Hosp,Dept Med, Seoul 137701, South Korea
[5] Ilsan Hosp, Div Hematooncol, Dept Med, Natl Hlth Insurance Corp, Koyang, South Korea
来源:
关键词:
Small cell lung cancer;
integrin ss 1;
E-cadherin;
rac1;
RHO-GTPASES;
PANCREATIC-CARCINOMA;
CATENIN EXPRESSION;
MEDIATED ADHESION;
SURVIVAL;
HYPERMETHYLATION;
ACTIVATION;
RECEPTORS;
BINDING;
IQGAP1;
D O I:
10.1111/j.1600-0463.2011.02788.x
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Integrin beta(1) mediates cellular adhesion to the extracellular matrix (ECM) and is correlated with highly invasive and metastatic behavior in small cell lung cancer (SCLC). E-cadherin (ECAD) is a calcium-dependent cell-cell adhesion receptor that restricts invasion of cells and reduces metastasis. Rac1 is involved in the regulation of the actin cytoskeleton, adhesion, migration, invasion, and tumor metastasis. The aim of this study was to examine integrin beta(1), ECAD and rac1 expression in SCLC and to analyze the prognostic value of these markers in patients with SCLC. We analyzed integrin beta(1), ECAD, and rac1 expression in 112 SCLC tissues by immunohistochemical staining. Correlative analyses between integrin beta(1), ECAD, and rac1 expression and cliniopathological factors were performed. A total of 65 patients had extensive disease (ED) (58%), and 47 had limited disease (LD) (42%). The median follow-up duration was 61 months (range: 14-117 months), and the median progression free survival (PFS) and overall survival (OS) were 6.1 months (range: 4.8-7.4 months) and 9.7 months (range: 8.1-11.3 months), respectively. The expression of integrin beta(1), ECAD, and rac1 protein was observed in 64, 73, and 99 of SCLC tissues, respectively. The correlative analyses between integrin beta(1), ECAD, or rac1 expression and various clinical parameters did not show any statistical significance. However, the ECAD expression was associated with OS in the entire cohort. In contrast, the expression of integrin beta(1) and rac1 was not associated with PFS or OS. In a subgroup analysis, patients with less than two metastasis had significantly longer OS (p = 0.047) if their tumors expressed integrin beta(1) compared to those without integrin beta(1) expression. In addition, OS was longer for patients with ECAD positive tumors compared to those whose tumors did not express ECAD in males (p = 0.032) and patients who never smoked (p < 0.001). Multivariate analysis showed that LD (p = 0.004), overall response rate (p = 0.003), and expression of ECAD (p = 0.015) were the independent good prognostic factors for OS. LD (p = 0.024), overall response rate (p < 0.001), and less than two metastasis (p = 0.003) were prognostic factors for longer PFS. These results suggest that ECAD expression may be useful as a prognostic indicator in patients with SCLC.
引用
收藏
页码:28 / 38
页数:11
相关论文
共 50 条